Myeloid TM6SF2 Deficiency Inhibits Atherosclerosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36139452/
Genetic variants in transmembrane 6 superfamily member 2 ( TM6SF2 ), such as E167K, are associated with atherosclerotic cardiovascular disease (ASCVD). Chronic inflammation and lipid-laden macrophage foam cell formation are the central pathogeneses in the development of atherosclerosis. This st ...
Conclusions: Myeloid TM6SF2 deficiency inhibits atherosclerosis development and is a potential therapeutic target for the treatment of atherogenesis.